Navigation Links
Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors: Results Presented at EASD 2011
Date:9/12/2011

elease for injectable suspension. It is an investigational medication for type 2 diabetes designed to deliver continuous therapeutic levels of exenatide in a single weekly dose. BYDUREON is a once-weekly formulation of exenatide, the active ingredient in BYETTA, which has been available in the U.S. since June 2005 and is used in more than 70 countries worldwide to improve glycemic control in adults with type 2 diabetes. BYDUREON received marketing authorization in the European Union in June 2011 and is currently under review in the U.S., with a Prescription Drug User Fee Action (PDUFA) date of January 28, 2012. It is available in the UK and will launch in other major European countries as soon as possible.

Study and Presentation Details:
DURATION-3
Presentation Number 778
Poster Session 062--Exenatide: twice daily to once weekly
Tuesday, Sept. 13, 2011, 1:30-2:30 p.m. Western European Summer TimeThe initial trial was an open-label study of 467 patients not achieving adequate glucose control using metformin therapy alone or in combination with a sulfonylurea. Subjects were randomized to receive treatment with BYDUREON or titrated doses of Lantus. The primary endpoint was reduction in A1C; secondary endpoints included change in body weight along with other parameters of glucose control, safety endpoints including hypoglycemia, cardiovascular risk biomarkers and patient-reported outcomes.

The comparator-controlled extension study evaluated sustained use of BYDUREON or Lantus and is ongoing. Interim results include data from patients (n=346) who entered the extension study and remained on their initial therapy for a total of 84 weeks. Post-hoc analyses examined changes in systolic blood pressure, diastolic blood pressure, LDL cholesterol, HDL cholesterol, triglycerides, total cholesterol and high-sensitivity C-reactive protein in patients with abnormal baseline values; correlat
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Alkermes, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
5. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
6. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
7. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
8. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
9. Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe
10. New Analyses Indicate that Divigel(R) (estradiol gel) 0.1% Is a Valuable Option for Certain Postmenopausal Women With Hot Flashes
11. Results and Additional Analyses From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... support to healthcare providers for behavioral health and ... secured $30 million in equity financing from new ... Drosos , President and Chief Executive Officer. ... and development of Assurex Health,s GeneSight ® ...
(Date:12/24/2014)... , Dec. 23, 2014 Tianyin Pharmaceutical ... that specializes in patented biopharmaceutical, modernized traditional Chinese ... (API) today announced that the Company achieved the ... Manufacturing Practice (GMP) certificate of TPI,s Qionglai Facility ... (CFDA). The public notice period is a significant ...
(Date:12/24/2014)... N.C. , Dec. 23, 2014  Medical Science ... As the key link between the medical device industry ... even more in the coming years as the device ... According to research by benchmarking firm, Best ... can gain an important edge is by harnessing new ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Role of Medical Science Liaisons Evolving in Medical Device Sector 2
... -- Global Information Inc. is pleased to announce ... market: Global Protein Therapeutics Market Forecast ... one of the most effective clinical methods to treat ... disorders. While worldwide healthcare spending has decline in the post- ...
... 2012 Hill-Rom Holdings, Inc. (NYSE: HRC ... Senior Vice President and President of Hill-Rom North America, ... Care business units.  This newly integrated North America business ... more than $1B.  The combination of Hill-Rom acute and ...
Cached Medicine Technology:New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015 2Hill-Rom Appoints Alton Shader President of Hill-Rom North America 2Hill-Rom Appoints Alton Shader President of Hill-Rom North America 3
(Date:12/25/2014)... 2014 The report “TS-1 (Colorectal Cancer) ... the current treatment landscape, unmet needs, current pipeline and ... an anti-cancer drug which is typically used for treating ... used for treating gastric cancer and pancreatic cancer. TS-1 ... drug was first approved in 1999 in Japan for ...
(Date:12/25/2014)... The short film “Color of Honor” by young ... a true 9/11 hero, Welles Remy Crowther. It has been ... hours of Nuremberg International Short Film Festival and the 8th ... screenwriter and director Luciana Lagana plays the mother of ... husband, Gregory Graham - Graham plays a heroic ...
(Date:12/25/2014)... December 25, 2014 Recently, LunaDress.co.uk has updated its ... and related accessories. Now, all of the models at LunaDress.co.uk come ... a groom lifts the wedding veil can turn out to be ... charm. A wedding veil can always bring surprise to a wedding. ... on how to choose veils for a big day . ...
(Date:12/25/2014)... By Dennis Thompson ... -- Researchers could be closing in on a "fountain of ... improve the health of older adults, a new study suggests. ... when given a drug that targets a genetic signaling pathway ... maker Novartis report. The experimental medication, a ...
(Date:12/25/2014)... 25, 2014 Residents at ... recently showed their generous spirit by providing holiday ... County Parenting Network- Grandparents Raising Grandchildren program. , ... around the largest Christmas tree on the campus ... by residents of the Abernethy Village Association (AVA). ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Retirement Community Residents Make Impact During Holiday Season 2
... Commission has,launched "Georgia Pecans Fit! for Breakfast," a ... is being promoted with new,findings from a survey ... of eating pecans and breakfast,recipes from a James ... News Release, go to:, http://www.prnewswire.com/mnr/georgiapecancommission/35429/ , Survey ...
... BRUNSWICK, N.J. The Rutgers University Cell and DNA ... than $57.8 million from the National Institutes of Health ... and the other will support investigations into the causes ... "Both awards were the result of a competitive selection ...
... the structural and neurochemical features of schizophrenia are present ... What processes tip the balance between the ultra-high risk ... mechanism is cerebral inflammation, studied by Dr. Bart van ... Biological Psychiatry . , Using positron emission tomography, ...
... Doctor Visits Abroad Even Easier, RADNOR, Pa., Oct. ... company, today announced the introduction of My Digital ID,the ... HTH,members to access all the information on their health ... rely on direct access to,HTH,s eligibility database to show ...
... took them were less likely to get venous thromboembolism ... of drugs widely used to lower cholesterol may have ... breast, lung, colon and other solid-organ cancers. , Research ... Philadelphia found that cancer patients taking statins had a ...
... Philadelphia, PA, October 27, 2008 Complications during pregnancy and ... in the body - are associated with an increased risk ... increases the risk for schizophrenia. The November 1st issue ... who show that the presence of a specific indicator of ...
Cached Medicine News:Health News:Photos: Georgia Pecan Campaign Emphasizes Nutritional Importance of Breakfast 2Health News:NIH awards Rutgers Cell and DNA Repository $57.8M 2Health News:Anti-inflammatory medications may become a treatment for schizophrenia 2Health News:HTH Worldwide Unveils First Digital Healthcare Card 2Health News:Statins Lower Risk of Clots in Cancer Patients 2Health News:The mental health dangers of birth hypoxia 2
CCR Medical conventional laryngoscopes....
CCR Medical conventional laryngoscopes....
CCR Medical conventional laryngoscopes....
CCR Medical conventional laryngoscope handles....
Medicine Products: